User profiles for Y. Oki
Yusuke OkiThe University of Tokyo Verified email at ac.jaxa.jp Cited by 1320 |
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
…, CP Miller, S TC Neuteboom, Y Oki… - Current cancer drug …, 2011 - ingentaconnect.com
The proteasome has emerged as an important clinically relevant target for the treatment of
hematologic malignancies. Since the Food and Drug Administration approved the first-in-…
hematologic malignancies. Since the Food and Drug Administration approved the first-in-…
Decitabine—bedside to bench
Y Oki, E Aoki, JPJ Issa - Critical reviews in oncology/hematology, 2007 - Elsevier
PURPOSE OF THE REVIEW: Epigenetic changes marked by DNA methylation are known to
contribute to the malignant transformation of cells by silencing critical genes. Decitabine …
contribute to the malignant transformation of cells by silencing critical genes. Decitabine …
Integrating ecosystem functions into restoration ecology—recent advances and future directions
…, JM Hermann, C Koch, SC Müller, Y Oki… - Restoration …, 2016 - Wiley Online Library
Including ecosystem functions into restoration ecology has been repeatedly suggested, yet
there is limited evidence that this is taking place without bias to certain habitats, species, or …
there is limited evidence that this is taking place without bias to certain habitats, species, or …
Reactor on-off antineutrino measurement with KamLAND
…, T Mitsui, D Motoki, K Nakamura, A Obata, A Oki, Y Oki… - Physical Review D, 2013 - APS
The recent long-term shutdown of Japanese nuclear reactors has resulted in a significantly
reduced reactor ν e flux at KamLAND. This running condition provides a unique opportunity …
reduced reactor ν e flux at KamLAND. This running condition provides a unique opportunity …
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
H Kantarjian, Y Oki, G Garcia-Manero, X Huang… - Blood, 2007 - ashpublications.org
Epigenetic therapy with hypomethylating drugs is now the standard of care in myelodysplastic
syndrome (MDS). Response rates remain low, and mechanism-based dose optimization …
syndrome (MDS). Response rates remain low, and mechanism-based dose optimization …
[HTML][HTML] Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
…, Á Illés, M Picardi, E Lech-Maranda, Y Oki… - … England Journal of …, 2018 - Mass Medical Soc
Background Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been
approved for relapsed and refractory Hodgkin’s lymphoma. Methods We conducted an open-…
approved for relapsed and refractory Hodgkin’s lymphoma. Methods We conducted an open-…
The geomorphology, color, and thermal properties of Ryugu: Implications for parent-body processes
INTRODUCTION The asteroid 162173 Ryugu is the target of the Japanese Hayabusa2 mission,
which is designed to collect samples from Ryugu’s surface and return them to Earth. We …
which is designed to collect samples from Ryugu’s surface and return them to Earth. We …
Double hit lymphoma: the MD A nderson C ancer C enter clinical experience
Y Oki, M Noorani, P Lin, RE Davis… - British journal of …, 2014 - Wiley Online Library
We report our experience with 129 cases of double hit lymphoma ( DHL ), defined as B‐cell
lymphoma with translocations and/or extra signals involving MYC plus BCL 2 and/or BCL 6. …
lymphoma with translocations and/or extra signals involving MYC plus BCL 2 and/or BCL 6. …
[HTML][HTML] DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes
…, W Zhu, S Pierce, Y Kondo, Y Oki… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose The current classification systems of myelodysplastic syndromes (MDS), including
the International Prognostic Scoring System (IPSS), do not fully reflect the molecular …
the International Prognostic Scoring System (IPSS), do not fully reflect the molecular …
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia
J Jelinek, Y Oki, V Gharibyan, C Bueso-Ramos… - blood, 2005 - ashpublications.org
… Two independent PCR and pyrosequencing reactions were performed to quantify the
presence of A on the antisense strand (x-axis) and T on the sense strand (y-axis). Correlation …
presence of A on the antisense strand (x-axis) and T on the sense strand (y-axis). Correlation …